Supraventricular Tachyarrhythmias

General Principles

  • SVTs—often recurrent, rarely persistent, and can result in visits to emergency departments and primary care physician offices.
  • Always begin with prompt assessment of hemodynamic stability and clinical status.
  • Diagnostic and therapeutic discussion that follows is aimed at hemodynamically stable patients. If a patient is clinically unstable based on signs and symptoms, immediately proceed to cardioversion per ACLS guidelines.

Definition

  • Tachyarrhythmias that require atrial or AV nodal tissue or both for their initiation and maintenance are termed SVT.
  • The QRS complex in most SVTs is narrow (QRS <120 ms).
  • SVTs can present as a wide-complex tachycardia (QRS ≥120 ms) if they are aberrantly conducted.

Classification

  • Initially classified by ECG to help understand likely underlying arrhythmia mechanism.
  • Diagnostic approach, based on the ECG, is summarized in Figure 7-1.
  • Narrow QRS complex tachyarrhythmias can be divided into those requiring only atrial tissue for initiation and maintenance (atrial tachycardia [AT], AF, and AFL) versus those that require the AV junction for perpetuation (JT, AVNRT, and AVRT).
  • Paroxysmal SVT—intermittent SVT other than AF, AFL, and multifocal AT (MAT).
Figure 7-1 Diagnostic approach to tachyarrhythmias.
Descriptive text is not available for this image
AF, atrial fibrillation; AFL, atrial flutter; AT, atrial tachycardia; AV, atrioventricular; AVNRT, atrioventricular nodal reentrant tachycardia; AVRT, atrioventricular reentrant tachycardia; EAT, ectopic atrial tachycardia; MAT, multifocal atrial tachycardia; O-AVRT, orthodromic AVRT; PAC, premature atrial complex; SANRT, sinoatrial nodal reentrant tachycardia; ST, sinus tachycardia; SVT, supraventricular tachyarrhythmia; VT, ventricular tachycardia; WPW, Wolff–Parkinson–White.

Epidemiology

  • The estimated prevalence of paroxysmal SVT is 2.25/1000, with an incidence of 35/100,000 person-years.1
  • In the absence of structural heart disease, SVT most commonly presents between ages 12 and 30 years.1
  • Women are twice as likely to develop SVT as men.1

There's more to see -- the rest of this topic is available only to subscribers.